Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thrombotic Risk and Cardiovascular Events in Patients With Revascularization Deferral After Fractional Flow Reserve Assessment.
Shiono Y, Kuramitsu S, Matsuo H, Horie K, Takashima H, Terai H, Kikuta Y, Ishihara T, Saigusa T, Sakamoto T, Suematsu N, Asano T, Tsujita K, Masamura K, Doijiri T, Toyota F, Ogita M, Kurita T, Matsuo A, Harada K, Yaginuma K, Sonoda S, Tanaka A, Yokoi H, Tanaka N; J-CONFIRM Registry Investigators. Shiono Y, et al. Among authors: sakamoto t. JACC Cardiovasc Interv. 2022 Feb 28;15(4):427-439. doi: 10.1016/j.jcin.2021.11.020. JACC Cardiovasc Interv. 2022. PMID: 35210049 Free article.
Long-term efficacy of edaravone in patients with acute myocardial infarction.
Tsujita K, Shimomura H, Kaikita K, Kawano H, Hokamaki J, Nagayoshi Y, Yamashita T, Fukuda M, Nakamura Y, Sakamoto T, Yoshimura M, Ogawa H. Tsujita K, et al. Among authors: sakamoto t. Circ J. 2006 Jul;70(7):832-7. doi: 10.1253/circj.70.832. Circ J. 2006. PMID: 16799234 Free article. Clinical Trial.
Microvascular coronary artery spasm presents distinctive clinical features with endothelial dysfunction as nonobstructive coronary artery disease.
Ohba K, Sugiyama S, Sumida H, Nozaki T, Matsubara J, Matsuzawa Y, Konishi M, Akiyama E, Kurokawa H, Maeda H, Sugamura K, Nagayoshi Y, Morihisa K, Sakamoto K, Tsujita K, Yamamoto E, Yamamuro M, Kojima S, Kaikita K, Tayama S, Hokimoto S, Matsui K, Sakamoto T, Ogawa H. Ohba K, et al. Among authors: sakamoto k, sakamoto t. J Am Heart Assoc. 2012 Oct;1(5):e002485. doi: 10.1161/JAHA.112.002485. Epub 2012 Oct 25. J Am Heart Assoc. 2012. PMID: 23316292 Free PMC article. Clinical Trial.
Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA, Yamagishi M, Sakamoto T, Takayama T, Hiro T, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. Kawashiri MA, et al. Among authors: sakamoto t. Cardiovasc Ther. 2013 Dec;31(6):335-43. doi: 10.1111/1755-5922.12027. Cardiovasc Ther. 2013. PMID: 23409830 Free article.
Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention.
Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, Nakamura S, Tsujita K, Tayama S, Hokimoto S, Sakamoto T, Nakao K, Oshima S, Sugiyama S, Ogawa H. Kaikita K, et al. Among authors: sakamoto t. J Atheroscler Thromb. 2014;21(1):64-76. doi: 10.5551/jat.18952. Epub 2013 Oct 1. J Atheroscler Thromb. 2014. PMID: 24088578 Free article.
Clinical features and prognosis of patients with coronary spasm-induced non-ST-segment elevation acute coronary syndrome.
Nakayama N, Kaikita K, Fukunaga T, Matsuzawa Y, Sato K, Horio E, Yoshimura H, Mizobe M, Takashio S, Tsujita K, Kojima S, Tayama S, Hokimoto S, Sakamoto T, Nakao K, Sugiyama S, Kimura K, Ogawa H. Nakayama N, et al. Among authors: sakamoto t. J Am Heart Assoc. 2014 May 8;3(3):e000795. doi: 10.1161/JAHA.114.000795. J Am Heart Assoc. 2014. PMID: 24811613 Free PMC article.
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Sakamoto T, Ogawa H, Nakao K, Hokimoto S, Tsujita K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Candesartan for Prevention of Cardiovascular Events after CYPHER™ or TAXUS™ Coronary Stenting) study investigators. Sakamoto T, et al. J Cardiol. 2016 Apr;67(4):371-7. doi: 10.1016/j.jjcc.2015.06.009. Epub 2015 Aug 4. J Cardiol. 2016. PMID: 26254019 Free article. Clinical Trial.
5,255 results